Navigation Links
Arpida to Discuss Strategy With Shareholders
Date:5/7/2009

REINACH, Switzerland, May 7 /PRNewswire-FirstCall/ -- Arpida Ltd. (SIX: ARPN) will today discuss potential strategic scenarios with its shareholders during the Annual General Meeting (AGM) which starts at 10am CET in Reinach, Switzerland.

After the negative FDA opinion regarding intravenous iclaprim, Arpida has initiated a thorough analysis with the aim to design a roadmap towards approval. The company was supported by international experts in this field.

As Arpida lacks both the time and the money to complete this path, a search for funding or other strategic options took place in parallel. The search for fresh funds did not yield any results as access to credit lines or equity funding is not available.

During the last months, Arpida, supported by external advisors, has explored all other strategic scenarios, including 'reverse mergers', takeovers, asset sales as well as liquidation as a last resort.

Board and Management currently pursue business development contacts with 72 companies, both inside Switzerland and abroad. Of these, Arpida focuses on 5 that have advanced into negotiations which are currently ongoing. At today's meeting no vote is planned on this item, as no concrete proposal is available at this time. If and when a major strategic proposal is made, shareholders will obviously be duly involved.

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statem
'/>"/>

SOURCE Arpida Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Arpida Announces Full Year 2008 Financial Results
2. Arpida to Restructure and Focus on Key Projects
3. Arpidas iclaprim MAA Accepted for Review by EMEA
4. Arpida Reports Interim Results for Six Months to 30 June 2008
5. Arpida Announces FDA Acceptance of the Iclaprim New Drug Application
6. Arpida Annual General Meeting of Shareholders Approves All Board Proposals
7. Leadership Change to Enable Arpida to Become a Fully Integrated Pharmaceutical Company
8. Arpida Announces Conference Call on 17 April
9. Arpida Announces Agenda Items for Shareholders Meeting
10. Arpida Submits New Drug Application for Intravenous Iclaprim for Treatment of Skin Infections
11. Arpida Announces Full Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... 4, 2015  Brooklyn residents now have a new ... pain and injuries. Nunzio Saulle , M.D., a ... of his NJS Physical Medicine and Rehabilitation (PM&R) practice ... March 5, 2015. Health Plus Management, LLC is managing ... at 1178 Flatbush Avenue. This new PM&R practice will ...
(Date:3/4/2015)... March 4, 2015 /CNW/ - Resverlogix Corp. (TSX:RVX) ... completed a collaborative research program with Emerald ... Fast Collective Evolution Technology (FACET), Emerald Logic ... measurements obtained from each of 798 patients ... clinical trials ASSERT, SUSTAIN and ASSURE. The ...
(Date:3/4/2015)... Pa. , March 4, 2015 /PRNewswire/ ... services and technology provider, today announced that ... 10 countries convened at its annual European ... to discuss the use of ... challenges. BioClinica,s eClinical technologies include: the Microsoft ...
(Date:3/4/2015)... 2015 Lancée par ... en décembre 2011, l,étude collaborative française ... qui compare   l es microsphères en ... dans le carcinome hépatocellulaire avancé, a recruté plus ... avancé   ; les résultats sont attendus fin ...
Breaking Biology Technology:NJS Physical Medicine & Rehabilitation Opening on Flatbush Avenue, Brooklyn, NY 2Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 2Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 3Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 4BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 2BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 3Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 2Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 3Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 4Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 5Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 6
... /Xinhua-PRNewswire-FirstCall/ -- American Oriental,Bioengineering, Inc. (NYSE: AOB ), ... manufacture and commercialization,of a broad range of prescription and ... the Company will present at the following,conferences:, ... held at the Grand Hyatt ...
... Agreement will enable HGS to generate revenue from available ... manufacturing capacity -, - Revenue potential from manufacturing alliances, including the alliance, ... ... years -, ROCKVILLE, Md., Sept. 4 Human Genome,Sciences, Inc. (Nasdaq: HGSI ) ...
... -- Company Maintains Full Year Guidance, ... International Limited (NYSE: MR ), a ... worldwide today announced its selected,unaudited financial results ... 2008.,During the quarter, Mindray successfully completed the ...
Cached Biology Technology:American Oriental Bioengineering Announces Participation in September Investor Conferences 2Human Genome Sciences Announces Process Development and Manufacturing Alliance With Hospira 2Human Genome Sciences Announces Process Development and Manufacturing Alliance With Hospira 3Human Genome Sciences Announces Process Development and Manufacturing Alliance With Hospira 4Mindray Medical International Announces Second Quarter 2008 Results 2Mindray Medical International Announces Second Quarter 2008 Results 3Mindray Medical International Announces Second Quarter 2008 Results 4Mindray Medical International Announces Second Quarter 2008 Results 5Mindray Medical International Announces Second Quarter 2008 Results 6Mindray Medical International Announces Second Quarter 2008 Results 7Mindray Medical International Announces Second Quarter 2008 Results 8Mindray Medical International Announces Second Quarter 2008 Results 9Mindray Medical International Announces Second Quarter 2008 Results 10Mindray Medical International Announces Second Quarter 2008 Results 11Mindray Medical International Announces Second Quarter 2008 Results 12Mindray Medical International Announces Second Quarter 2008 Results 13Mindray Medical International Announces Second Quarter 2008 Results 14Mindray Medical International Announces Second Quarter 2008 Results 15Mindray Medical International Announces Second Quarter 2008 Results 16Mindray Medical International Announces Second Quarter 2008 Results 17
(Date:2/12/2015)... NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market, announced ... DISTRIBUTED METHOD AND SYSTEM TO IMPROVE COLLABORATIVE ... establishes NXT-ID,s position in the emerging "Internet of Things" ... for multiple devices to collaborate with one another to ...
(Date:2/5/2015)... PARK, North Carolina , 5. Februar ... 35. Jahr als spezialisiertes Logistikunternehmen und hat ... als einzige klinische Logistikfirma (Clinical Logistics Organization ... Kernbotschaft der neuen Kampagne lautet First ... Lieferungen. Foto: http://photos.prnewswire.com/prnh/20150205/173753 ...
(Date:2/5/2015)... 2015   Marvin Test Solutions , ... test solutions for military, aerospace, and manufacturing ... TS-323 GENASYS Test Platform to ... is a high-performance PXI-based system designed to ... require performance functional testing. GENASYS features a ...
Breaking Biology News(10 mins):NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4
... open letter addressed to President Barack Obama and the ... that the currently stated objectives in limiting the climatic ... to take clear leadership towards meet the objectives of ... to avert a "global climatic catastrophe". ...
... animals ever to have walked the face of the earth ... a paper published today in the Zoological Society of London,s ... the original statistical model used to calculate dinosaur mass is ... for the mass of Apatosaurus louisae , one of ...
... (June 21, 2009) Notch signaling helps determine the fate ... of organisms, including humans. In an article that appears in ... at Baylor College of Medicine report that a new finding ... in the fruit fly could explain the mystery behind an ...
Cached Biology News:Leading scientists and scholars urge action on climate issues 2Fate in fly sensory organ precursor cells could explain human immune disorder 2Fate in fly sensory organ precursor cells could explain human immune disorder 3